ATC Group: L01FD04 Trastuzumab deruxtecan

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L01FD04 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L01 Antineoplastic agents
3 L01F Monoclonal antibodies and antibody drug conjugates
4 L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
5 L01FD04 Trastuzumab deruxtecan

Active ingredients in L01FD04

Active Ingredient

Trastuzumab deruxtecan is a HER2-targeted antibody-drug conjugate. The antibody is a humanised anti-HER2 IgG1 attached to deruxtecan, a topoisomerase I inhibitor (DXd) bound by a tetrapeptide-based cleavable linker. The antibody-drug conjugate is stable in plasma. The function of the antibody portion is to bind to HER2 expressed on the surface of certain tumour cells.

Related product monographs

Document Type Information Source  
 ENHERTU Powder for concentrate for solution for infusion MPI, EU: SmPC European Medicines Agency (EU)
 ENHERTU Powder for solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)

Medicines in this ATC group

United States (US)

Austria (AT)

Croatia (HR)

Estonia (EE)

Finland (FI)

France (FR)

Ireland (IE)

Israel (IL)

Italy (IT)

Japan (JP)

Lithuania (LT)

Poland (PL)

Romania (RO)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.